NCT04367311 - Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

January 31, 2026

Conditions

Lung CancerNSCLC

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg

DRUG

Docetaxel

Docetaxel 60-75 mg/m\^2

DRUG

Cisplatin

60-75 mg/m\^2

DRUG

Pemetrexed

Pemetrexed 500mg/m\^2

Trial Locations (10)

10016

RECRUITING

New York University Clinical Cancer Center, New York

17033

RECRUITING

Penn State Cancer Institute, Hershey

22908

RECRUITING

University of Virginia Health System, Charlottesville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

46202

RECRUITING

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

53705

RECRUITING

University of Wisconsin, Madison

60611

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

85234

WITHDRAWN

Banner MD Anderson Cancer Center, Gilbert

07922

RECRUITING

Summit Health, Berkeley Heights

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick